[
  {
    "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
    "bbox": [
      112,
      131,
      1000,
      141
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "individually as a \"Party\" and collectively as the \"Parties\".",
    "bbox": [
      112,
      145,
      543,
      157
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
    "bbox": [
      397,
      83,
      947,
      94
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
    "bbox": [
      156,
      113,
      1000,
      127
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
    "bbox": [
      112,
      131,
      1000,
      141
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "individually as a \"Party\" and collectively as the \"Parties\".",
    "bbox": [
      112,
      145,
      543,
      157
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "RECITALS",
    "bbox": [
      630,
      192,
      715,
      203
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
    "bbox": [
      157,
      221,
      654,
      235
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
    "bbox": [
      157,
      253,
      855,
      266
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
    "bbox": [
      156,
      284,
      1000,
      297
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
    "bbox": [
      111,
      300,
      1000,
      312
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "set forth below.",
    "bbox": [
      111,
      317,
      223,
      327
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
    "bbox": [
      155,
      347,
      1000,
      359
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
    "bbox": [
      112,
      363,
      967,
      375
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      629,
      409,
      716,
      420
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      617,
      425,
      727,
      435
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
    "bbox": [
      156,
      455,
      1000,
      468
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "elsewhere in this Agreement:",
    "bbox": [
      112,
      471,
      323,
      483
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
    "bbox": [
      156,
      495,
      1000,
      507
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
    "bbox": [
      111,
      510,
      1000,
      522
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
    "bbox": [
      110,
      526,
      1000,
      538
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "or prevention of disease or to affect the structure or function of the body..",
    "bbox": [
      112,
      542,
      645,
      554
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
    "bbox": [
      156,
      572,
      1000,
      585
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
    "bbox": [
      112,
      589,
      1000,
      599
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
    "bbox": [
      110,
      604,
      1000,
      615
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
    "bbox": [
      111,
      619,
      1000,
      631
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
    "bbox": [
      111,
      635,
      1000,
      647
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
    "bbox": [
      110,
      650,
      1000,
      662
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
    "bbox": [
      113,
      666,
      1000,
      677
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
    "bbox": [
      112,
      682,
      986,
      693
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1",
    "bbox": [
      666,
      697,
      679,
      707
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
    "bbox": [
      133,
      1000,
      574,
      1000
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
    "bbox": [
      397,
      83,
      947,
      94
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
    "bbox": [
      156,
      113,
      1000,
      127
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
    "bbox": [
      112,
      131,
      1000,
      141
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "individually as a \"Party\" and collectively as the \"Parties\".",
    "bbox": [
      112,
      145,
      543,
      157
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "RECITALS",
    "bbox": [
      630,
      192,
      715,
      203
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
    "bbox": [
      157,
      221,
      654,
      235
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
    "bbox": [
      157,
      253,
      855,
      266
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
    "bbox": [
      156,
      284,
      1000,
      297
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
    "bbox": [
      111,
      300,
      1000,
      312
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "set forth below.",
    "bbox": [
      111,
      317,
      223,
      327
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
    "bbox": [
      155,
      347,
      1000,
      359
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
    "bbox": [
      112,
      363,
      967,
      375
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      629,
      409,
      716,
      420
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      617,
      425,
      727,
      435
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
    "bbox": [
      156,
      455,
      1000,
      468
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "elsewhere in this Agreement:",
    "bbox": [
      112,
      471,
      323,
      483
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
    "bbox": [
      156,
      495,
      1000,
      507
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
    "bbox": [
      111,
      510,
      1000,
      522
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
    "bbox": [
      110,
      526,
      1000,
      538
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "or prevention of disease or to affect the structure or function of the body..",
    "bbox": [
      112,
      542,
      645,
      554
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
    "bbox": [
      156,
      572,
      1000,
      585
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
    "bbox": [
      112,
      589,
      1000,
      599
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
    "bbox": [
      110,
      604,
      1000,
      615
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
    "bbox": [
      111,
      619,
      1000,
      631
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
    "bbox": [
      111,
      635,
      1000,
      647
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
    "bbox": [
      110,
      650,
      1000,
      662
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
    "bbox": [
      113,
      666,
      1000,
      677
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
    "bbox": [
      112,
      682,
      986,
      693
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1",
    "bbox": [
      666,
      697,
      679,
      707
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
    "bbox": [
      133,
      1000,
      574,
      1000
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
    "bbox": [
      397,
      83,
      947,
      94
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
    "bbox": [
      156,
      113,
      1000,
      127
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
    "bbox": [
      112,
      131,
      1000,
      141
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "individually as a \"Party\" and collectively as the \"Parties\".",
    "bbox": [
      112,
      145,
      543,
      157
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "RECITALS",
    "bbox": [
      630,
      192,
      715,
      203
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
    "bbox": [
      157,
      221,
      654,
      235
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
    "bbox": [
      157,
      253,
      855,
      266
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
    "bbox": [
      156,
      284,
      1000,
      297
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
    "bbox": [
      111,
      300,
      1000,
      312
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "set forth below.",
    "bbox": [
      111,
      317,
      223,
      327
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
    "bbox": [
      155,
      347,
      1000,
      359
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
    "bbox": [
      112,
      363,
      967,
      375
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      629,
      409,
      716,
      420
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      617,
      425,
      727,
      435
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
    "bbox": [
      156,
      455,
      1000,
      468
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "elsewhere in this Agreement:",
    "bbox": [
      112,
      471,
      323,
      483
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
    "bbox": [
      156,
      495,
      1000,
      507
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
    "bbox": [
      111,
      510,
      1000,
      522
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
    "bbox": [
      110,
      526,
      1000,
      538
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "or prevention of disease or to affect the structure or function of the body..",
    "bbox": [
      112,
      542,
      645,
      554
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
    "bbox": [
      156,
      572,
      1000,
      585
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
    "bbox": [
      112,
      589,
      1000,
      599
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
    "bbox": [
      110,
      604,
      1000,
      615
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
    "bbox": [
      111,
      619,
      1000,
      631
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
    "bbox": [
      111,
      635,
      1000,
      647
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
    "bbox": [
      110,
      650,
      1000,
      662
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
    "bbox": [
      113,
      666,
      1000,
      677
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
    "bbox": [
      112,
      682,
      986,
      693
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1",
    "bbox": [
      666,
      697,
      679,
      707
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
    "bbox": [
      133,
      1000,
      574,
      1000
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
    "bbox": [
      397,
      83,
      947,
      94
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
    "bbox": [
      156,
      113,
      1000,
      127
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
    "bbox": [
      112,
      131,
      1000,
      141
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "individually as a \"Party\" and collectively as the \"Parties\".",
    "bbox": [
      112,
      145,
      543,
      157
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "RECITALS",
    "bbox": [
      630,
      192,
      715,
      203
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
    "bbox": [
      157,
      221,
      654,
      235
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
    "bbox": [
      157,
      253,
      855,
      266
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
    "bbox": [
      156,
      284,
      1000,
      297
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
    "bbox": [
      111,
      300,
      1000,
      312
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "set forth below.",
    "bbox": [
      111,
      317,
      223,
      327
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
    "bbox": [
      155,
      347,
      1000,
      359
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
    "bbox": [
      112,
      363,
      967,
      375
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      629,
      409,
      716,
      420
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      617,
      425,
      727,
      435
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
    "bbox": [
      156,
      455,
      1000,
      468
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "elsewhere in this Agreement:",
    "bbox": [
      112,
      471,
      323,
      483
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
    "bbox": [
      156,
      495,
      1000,
      507
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
    "bbox": [
      111,
      510,
      1000,
      522
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
    "bbox": [
      110,
      526,
      1000,
      538
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "or prevention of disease or to affect the structure or function of the body..",
    "bbox": [
      112,
      542,
      645,
      554
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
    "bbox": [
      156,
      572,
      1000,
      585
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
    "bbox": [
      112,
      589,
      1000,
      599
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
    "bbox": [
      110,
      604,
      1000,
      615
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
    "bbox": [
      111,
      619,
      1000,
      631
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
    "bbox": [
      111,
      635,
      1000,
      647
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
    "bbox": [
      110,
      650,
      1000,
      662
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
    "bbox": [
      113,
      666,
      1000,
      677
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
    "bbox": [
      112,
      682,
      986,
      693
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1",
    "bbox": [
      666,
      697,
      679,
      707
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
    "bbox": [
      133,
      1000,
      574,
      1000
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
    "bbox": [
      397,
      83,
      947,
      94
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
    "bbox": [
      156,
      113,
      1000,
      127
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
    "bbox": [
      112,
      131,
      1000,
      141
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "individually as a \"Party\" and collectively as the \"Parties\".",
    "bbox": [
      112,
      145,
      543,
      157
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "RECITALS",
    "bbox": [
      630,
      192,
      715,
      203
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
    "bbox": [
      157,
      221,
      654,
      235
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
    "bbox": [
      157,
      253,
      855,
      266
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
    "bbox": [
      156,
      284,
      1000,
      297
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
    "bbox": [
      111,
      300,
      1000,
      312
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "set forth below.",
    "bbox": [
      111,
      317,
      223,
      327
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
    "bbox": [
      155,
      347,
      1000,
      359
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
    "bbox": [
      112,
      363,
      967,
      375
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      629,
      409,
      716,
      420
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      617,
      425,
      727,
      435
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
    "bbox": [
      156,
      455,
      1000,
      468
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "elsewhere in this Agreement:",
    "bbox": [
      112,
      471,
      323,
      483
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
    "bbox": [
      156,
      495,
      1000,
      507
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
    "bbox": [
      111,
      510,
      1000,
      522
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
    "bbox": [
      110,
      526,
      1000,
      538
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "or prevention of disease or to affect the structure or function of the body..",
    "bbox": [
      112,
      542,
      645,
      554
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
    "bbox": [
      156,
      572,
      1000,
      585
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
    "bbox": [
      112,
      589,
      1000,
      599
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
    "bbox": [
      110,
      604,
      1000,
      615
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
    "bbox": [
      111,
      619,
      1000,
      631
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
    "bbox": [
      111,
      635,
      1000,
      647
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
    "bbox": [
      110,
      650,
      1000,
      662
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
    "bbox": [
      113,
      666,
      1000,
      677
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
    "bbox": [
      112,
      682,
      986,
      693
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1",
    "bbox": [
      666,
      697,
      679,
      707
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
    "bbox": [
      133,
      1000,
      574,
      1000
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
    "bbox": [
      397,
      83,
      947,
      94
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
    "bbox": [
      156,
      113,
      1000,
      127
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
    "bbox": [
      112,
      131,
      1000,
      141
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "individually as a \"Party\" and collectively as the \"Parties\".",
    "bbox": [
      112,
      145,
      543,
      157
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "RECITALS",
    "bbox": [
      630,
      192,
      715,
      203
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
    "bbox": [
      157,
      221,
      654,
      235
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
    "bbox": [
      157,
      253,
      855,
      266
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
    "bbox": [
      156,
      284,
      1000,
      297
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
    "bbox": [
      111,
      300,
      1000,
      312
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "set forth below.",
    "bbox": [
      111,
      317,
      223,
      327
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
    "bbox": [
      155,
      347,
      1000,
      359
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
    "bbox": [
      112,
      363,
      967,
      375
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      629,
      409,
      716,
      420
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      617,
      425,
      727,
      435
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
    "bbox": [
      156,
      455,
      1000,
      468
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "elsewhere in this Agreement:",
    "bbox": [
      112,
      471,
      323,
      483
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
    "bbox": [
      156,
      495,
      1000,
      507
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
    "bbox": [
      111,
      510,
      1000,
      522
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
    "bbox": [
      110,
      526,
      1000,
      538
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "or prevention of disease or to affect the structure or function of the body..",
    "bbox": [
      112,
      542,
      645,
      554
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
    "bbox": [
      156,
      572,
      1000,
      585
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
    "bbox": [
      112,
      589,
      1000,
      599
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
    "bbox": [
      110,
      604,
      1000,
      615
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
    "bbox": [
      111,
      619,
      1000,
      631
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
    "bbox": [
      111,
      635,
      1000,
      647
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
    "bbox": [
      110,
      650,
      1000,
      662
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
    "bbox": [
      113,
      666,
      1000,
      677
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
    "bbox": [
      112,
      682,
      986,
      693
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1",
    "bbox": [
      666,
      697,
      679,
      707
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
    "bbox": [
      133,
      1000,
      574,
      1000
    ],
    "label": 33,
    "category": "Audit Rights"
  }
]